Abstract
Clopidogrel, a drug belonging to the thienopyridine class of antiplatelet agents, has been utilized either as a standalone medication or in combination with aspirin for averting vascular complications in patients afflicted with atherothrombotic conditions. The selective and irreversible blockade of the P2Y12 receptor by clopidogrel makes it a potent inhibitor of platelet activation and aggregation. In patients with acute coronary syndromes or undergoing percutaneous interventions, combining clopidogrel with aspirin is a crucial approach to antiplatelet therapy. The aim of this review article is to investigate the factors that contribute to clopidogrel resistance, mechanisms involved in clopidogrel resistance, evaluate it through laboratory methods and clinical implications of clopidogrel resistance. Additionally, the article explores the clinical importance of Clopidogrel Resistance and its correlation with harmful cardiovascular events. The paper concludes by proposing potential solutions to this resistance and suggesting the usage of alternative antiplatelet from the new generation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
